Dysregulation of the C/EBPα differentiation pathway in human cancer

Steffen Koschmieder, Balazs Halmos, Elena Levantini, Daniel G. Tenen

Research output: Contribution to journalReview article

132 Citations (Scopus)

Abstract

While much is known about aberrant pathways affecting cell growth and apoptosis, our understanding of another critical step of neoplastic transformation, differentiation arrest, remains poor. The differentiation- inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development. Studies investigating the function of this protein in hematopoietic malignancies as well as in lung and skin cancer have revealed numerous ways how tumor cells abrogate C/EBPα function. Genetic and global expression analysis of acute myeloid leukemia (AML) cases identifies C/EBPα-deficient AML as a separate entity yielding novel classification schemes. In patients with a dysfunctional C/EBPα pathway, targeted therapies may overcome the block in differentiation, and in combination with conventional chemotherapy, may lead to complete eradication of the malignant clone. Overall, a better understanding of the mechanisms of how C/EBPα dysregulation participates in the neoplastic process has opened new gateways for differentiation biology research.

Original languageEnglish (US)
Pages (from-to)619-628
Number of pages10
JournalJournal of Clinical Oncology
Volume27
Issue number4
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

CCAAT-Enhancer-Binding Protein-alpha
Neoplasms
Acute Myeloid Leukemia
Neoplastic Processes
Adipogenesis
Skin Neoplasms
Hematologic Neoplasms
Lung Neoplasms
Transcription Factors
Clone Cells
Apoptosis
Glucose
Drug Therapy
Lung
Growth
Research
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Dysregulation of the C/EBPα differentiation pathway in human cancer. / Koschmieder, Steffen; Halmos, Balazs; Levantini, Elena; Tenen, Daniel G.

In: Journal of Clinical Oncology, Vol. 27, No. 4, 01.02.2009, p. 619-628.

Research output: Contribution to journalReview article

Koschmieder, Steffen ; Halmos, Balazs ; Levantini, Elena ; Tenen, Daniel G. / Dysregulation of the C/EBPα differentiation pathway in human cancer. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 4. pp. 619-628.
@article{2179517619ad4454a824e640c1934f3d,
title = "Dysregulation of the C/EBPα differentiation pathway in human cancer",
abstract = "While much is known about aberrant pathways affecting cell growth and apoptosis, our understanding of another critical step of neoplastic transformation, differentiation arrest, remains poor. The differentiation- inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development. Studies investigating the function of this protein in hematopoietic malignancies as well as in lung and skin cancer have revealed numerous ways how tumor cells abrogate C/EBPα function. Genetic and global expression analysis of acute myeloid leukemia (AML) cases identifies C/EBPα-deficient AML as a separate entity yielding novel classification schemes. In patients with a dysfunctional C/EBPα pathway, targeted therapies may overcome the block in differentiation, and in combination with conventional chemotherapy, may lead to complete eradication of the malignant clone. Overall, a better understanding of the mechanisms of how C/EBPα dysregulation participates in the neoplastic process has opened new gateways for differentiation biology research.",
author = "Steffen Koschmieder and Balazs Halmos and Elena Levantini and Tenen, {Daniel G.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1200/JCO.2008.17.9812",
language = "English (US)",
volume = "27",
pages = "619--628",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Dysregulation of the C/EBPα differentiation pathway in human cancer

AU - Koschmieder, Steffen

AU - Halmos, Balazs

AU - Levantini, Elena

AU - Tenen, Daniel G.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - While much is known about aberrant pathways affecting cell growth and apoptosis, our understanding of another critical step of neoplastic transformation, differentiation arrest, remains poor. The differentiation- inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development. Studies investigating the function of this protein in hematopoietic malignancies as well as in lung and skin cancer have revealed numerous ways how tumor cells abrogate C/EBPα function. Genetic and global expression analysis of acute myeloid leukemia (AML) cases identifies C/EBPα-deficient AML as a separate entity yielding novel classification schemes. In patients with a dysfunctional C/EBPα pathway, targeted therapies may overcome the block in differentiation, and in combination with conventional chemotherapy, may lead to complete eradication of the malignant clone. Overall, a better understanding of the mechanisms of how C/EBPα dysregulation participates in the neoplastic process has opened new gateways for differentiation biology research.

AB - While much is known about aberrant pathways affecting cell growth and apoptosis, our understanding of another critical step of neoplastic transformation, differentiation arrest, remains poor. The differentiation- inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development. Studies investigating the function of this protein in hematopoietic malignancies as well as in lung and skin cancer have revealed numerous ways how tumor cells abrogate C/EBPα function. Genetic and global expression analysis of acute myeloid leukemia (AML) cases identifies C/EBPα-deficient AML as a separate entity yielding novel classification schemes. In patients with a dysfunctional C/EBPα pathway, targeted therapies may overcome the block in differentiation, and in combination with conventional chemotherapy, may lead to complete eradication of the malignant clone. Overall, a better understanding of the mechanisms of how C/EBPα dysregulation participates in the neoplastic process has opened new gateways for differentiation biology research.

UR - http://www.scopus.com/inward/record.url?scp=59149096563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149096563&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.17.9812

DO - 10.1200/JCO.2008.17.9812

M3 - Review article

VL - 27

SP - 619

EP - 628

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -